Scale -

  • Revenue is 368 Rs Cr; Annual Growth is 18 %; Continuous Growth over 3 years; 5 Year CAGR is 14 %
  • Ebitda is 49.85 Rs Cr; Continuous Growth over 3 years
  • PBT is 5.66 Rs Cr; 5 Year CAGR is -13 %
  • PAT is 17.97 Rs Cr; 5 Year CAGR is -15 %

Profitability -

  • PBDIT Margin is 13.54 %; Annual Decline is -13 %; Continuous Decline over 3 years; 5 Year CAGR is -13 %
  • PAT Margin is 4.88 %; Annual Decline is -25 %; Continuous Decline over 3 years; 5 Year CAGR is -26 %
  • Quarterly Ebitda Margin is 12 %; Continuous Decline over 3 Quarters

Return -

  • Asset Turnover is 47 %; Continuous Growth over 3 years; in Bottom Quartile
  • ROA is 1.51 %; Annual Decline is -33 %; 5 Year CAGR is -27 %
  • ROE is 2.06 %; Annual Decline is -34 %; 5 Year CAGR is -31 %
  • ROCE is 4.94 %; in Bottom Quartile; 5 Year CAGR is -17 %

Efficiency -

  • Operating cash flow is -33.96 Rs Cr; Annual Decline is -269 %; Continuous Decline over 3 years; in Bottom Quartile

Solvancy -

  • Contingent Liabilities is 0 Rs Cr; Annual Decline is -100 %
  • Long term Debt is 26.18 Rs Cr; Annual Growth is 59 %; 5 Year CAGR is 33 %
  • Debt/Equity is 0.19; Continuous Growth over 3 years
  • Total Debt is 114 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 31 %

Quality -

  • Current Tax/PAT is 25 %; Annual Decline is -20 %; Continuous Decline over 3 years
  • Other Expenses/Total Expenses is 8 %; in Bottom Quartile
  • Operating cashflow/ebitda is -68 %; Annual Decline is -259 %; Continuous Decline over 3 years; in Bottom Quartile
  • Operating cashflow/PAT is -189 %; Annual Decline is -319 %; Continuous Decline over 3 years; in Bottom Quartile
  • Change in Inventories/Total Expenses is -2 %; Annual Growth is 64 %; Continuous Growth over 3 years
  • Exceptional Items/PBT is 0 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem

Sector
Major Subsidiaries/Associates
Key Clients

Products

Products
Product details

Operations

Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Shivalik Rasayan lifts Medicamen Biotech stake to 42.57% via warrant conversion
Read More
  • Past/current
Shivalik Rasayan Ltd Estimates – BSE:SHIVALIK
Read More
  • Past/current